Abstract
D-dimer testing is widely recommended for rapid exclusion of venous thromboembolism (VTE) in suspected outpatients. This results in important cost savings on imaging and reduces the length of stay in the ED. Point-of-care (POC) testing will be useful due to its short turnaround time. Safety is of primary concern and this requires the validation of an appropriate cut-off that will result in a high negative predictive value (NPV). The precision of the assay around the cut-off is another determining factor because it will influence the probability of misclassification (i.e. false-negative or false-positive if the ‘true value' is above or below the cut-off, respectively). The aim of the study was to evaluate the potential utility of the Triage® D-dimer POC device (Biosite) for VTE exclusion by comparison with the well validated rapid quantitative VIDAS® D-dimer ELISA (bioMérieux).
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
